ClinicalTrials.gg

Myelodysplastic Syndromes clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,997 studies for Myelodysplastic Syndromes across more than 10 countries. 323 are recruiting or about to start. 698 of them are mainly about Myelodysplastic Syndromes (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 3 narrower conditions too, such as Hemoglobinuria, Paroxysmal: 2,220 studies, 370 open.

ClinicalTrials.gov finds 2,698 studies for Myelodysplastic Syndromes. How that becomes 1,997 here

This page counts the studies the registry files under Myelodysplastic Syndromes, and those it files under no condition that list Myelodysplastic Syndromesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,698Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −220Filed under a narrower condition, counted on its own pageHemoglobinuria, Paroxysmal 172 · Anemia, Refractory, with Excess of Blasts 41 · Anemia, Refractory 7
  3. −207List Myelodysplastic Syndromes as a condition, but the registry did not file them under itMost often written as “Previously Treated Myelodysplastic Syndromes” (55), “de Novo Myelodysplastic Syndromes” (48), and “Secondary Myelodysplastic Syndromes” (41). The registry filed them under other conditions only, most often Leukemia, Myeloid, Acute (166) and Congenital Abnormalities (62).
  4. −274Match it another way121 name it in the title, 42 in a keyword, and 111 by a synonym or other text the search reads.
  5. 1,997The count on this page27 of them list Myelodysplastic Syndromes in their own words; the registry filed them under no condition.

Status

Completed
975
Terminated
325
Recruiting
264
Active, not recruiting
134
Status unknown
131
Withdrawn
84

Phase

Phase 2
1,023
Phase 1
714
Phase 3
154
Phase 4
26
Early Phase 1
19

Where

United States
1,363
France
198
Germany
160
Italy
134
China
118
Canada
116

Who develops what

Add Myelodysplastic Syndromes to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 26 programs from 15 companies, 7 with this as their studies’ main aim; 3 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Johnson & Johnson, Fosun Pharma and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AzacitidineRecent, repeated
Evidence
  • NCT06641414 · Ascentage Pharma Group International · Phase 3 · live · background · “Azacitidine Injection” · registered Oct 2024
  • NCT06196203 · Akeso · Phase 2 · live · background · “Azacitidine” · registered Dec 2023
  • NCT05428969 · Faron Pharmaceuticals Ltd · Phase 2 · live · background · “Azacitidine” · registered Jun 2022
  • NCT05367401 · Novartis · Phase 2 · background · “Azacitidine” · registered Apr 2022
  • NCT05201066 · Novartis · Phase 2 · live · background · “azacitidine” · registered Jan 2022
Bristol-Myers Squibb29% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 4 generics authorized45 studies
venetoclaxRecent, repeated
Evidence
  • NCT06563804 · Servier Bio-Innovation LLC · Phase 2 · background · “Venetoclax” · registered Aug 2024
  • NCT05428969 · Faron Pharmaceuticals Ltd · Phase 2 · live · background · “Venetoclax” · registered Jun 2022
  • NCT05201066 · Novartis · Phase 2 · live · background · “venetoclax” · registered Jan 2022
  • NCT04988555 · Sumitomo Pharma Co., Ltd. · Phase 2 · live · background · “Venetoclax” · registered Jul 2021
  • NCT04812548 · Novartis · Phase 2 · background · “venetoclax” · registered Feb 2021
AbbVie64% of its industry studiesUS: AbbVie (FDA 2016)EU: AbbVie (EMA 2016)33 studies
Epoetin AlfaRecent, repeated
Evidence
  • NCT07422480 · Takeda · Phase 3 · live · comparator · “Epoetin Alfa” · registered Feb 2026
  • NCT05949684 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Epoetin Alfa” · registered Jul 2023
  • NCT03682536 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Epoetin alfa” · registered Sep 2018
  • NCT01034657 · Novartis · Phase 2 · background · “Epoetin Alfa” · registered Dec 2009
Johnson & Johnson55% of its industry studiesUS: Amgen (FDA 1989) + 1 otherEU: Hoffmann-La Roche (EMA 1997) + 6 others22 studies
DecitabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT05835011 · Otsuka Holdings Co., Ltd. · Phase 2 · background · “Decitabine/Cedazuridine” · registered Apr 2023
  • NCT05201066 · Novartis · Phase 2 · live · background · “decitabine” · registered Jan 2022
  • NCT04878432 · Novartis · Phase 2 · background · “Decitabine” · registered May 2021
  • NCT03306264 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Dacogen” · registered Oct 2017
  • NCT03184935 · Sclnow Biotechnology Co., Ltd. · Phase 2 · background · “Decitabine” · registered Jun 2017
Eisai Co., Ltd.27% of its industry studies22 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
elritercept☆ Track2 live phase-3 studies: NCT06499285, NCT07422480Takeda
roxadustatApproved: EU 2021☆ Track1 live phase-3 study: NCT07722988Kyntra Bio

The 2 in phase 3 with the nearest primary completion, of 26 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.SEL-120, romaciclib, silevertinib · Ryvu Therapeutics SA · Phase 2 named, not the main aimstudied with ruxolitinibNCT06987058 RVU120 Rollover Study — primary endpoint: Incidence of Adverse Events (Safety and Tolerability) · 14 enrolled
  • 30 Dec 2026 est.pacritinib · Swedish Orphan Biovitrum · Phase 2 registry mapping onlyNCT06782373 A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) — primary endpoint: Overall Response Rate (ORR), defined as achieving Partial Clinical Response or better at any time during the double-blind treatment period. · 156 enrolled
  • 14 Jul 2027 est.momelotinib · GlaxoSmithKline · Phase 2 main aimNCT06847867 A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome — primary endpoint: Percentage of participants with Red Blood Cells - transfusion independence (RBC-TI) for at least 12 weeks, rolling over 24 weeks · 80 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myelodysplastic Syndromes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 53 open · Alkylating agents 34 open · Tyrosine kinase inhibitors (TKIs) 16 open · Calcineurin inhibitors 8 open · JAK inhibitors 8 open

Coming up

132studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger. 57 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 17 (6%) take healthy volunteers.

Recruiting studies that take each age, of 264
AgeWomenMen
1041 (16%)41 (16%)
18252 (95%)252 (95%)
30250 (95%)250 (95%)
40246 (93%)246 (93%)
50244 (92%)244 (92%)
65244 (92%)244 (92%)
75218 (83%)218 (83%)
85183 (69%)183 (69%)

Across all 1,997 studies, recruiting or not: 30% stop at 75 or younger and 18% at 65; 26% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myelodysplastic Syndromes studies take

Of 279 phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 66 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 152 mo31–86 · 220 studies44 mo30–72 · 84 studies55 mo35–92 · 136 studies
Phase 1/278 mo49–110 · 109 studies78 mo56–91 · 41 studies72 mo49–142 · 68 studies
Phase 266 mo40–104 · 279 studies40 mo30–62 · 52 studies76 mo44–116 · 227 studies
Phase 348 mo37–95 · 46 studies42 mo33–52 · 26 studies—
Interventional, no phase65 mo40–125 · 58 studies—66 mo33–125 · 57 studies
Observational84 mo34–… · 102 studies—96 mo51–… · 79 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,997. Browse all 1,997 → or search them.